These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16126790)

  • 1. Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
    Weinblatt ME
    Ann Rheum Dis; 2005 Nov; 64(11):1529-31. PubMed ID: 16126790
    [No Abstract]   [Full Text] [Related]  

  • 2. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 3. [TNF-alpha blocker in rheumatoid arthritis. Who should be treated with the new substances?].
    MMW Fortschr Med; 2000 Nov; 142(44):6. PubMed ID: 11107796
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritis.
    Strand V
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):8, 13-4. PubMed ID: 17491581
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J; Alten R; Burkhardt H; Edelmann E; Gromnica-Ihle E; Krause A; Krüger K; Manger B; Lorenz H; Müller-Ladner U; Nüsslein H; Pott HG; Tony H; Schneider M
    MMW Fortschr Med; 2006 Oct; 148(42):38-42; quiz 43. PubMed ID: 17621798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 8. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 11. Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
    Lu CY; Williams KM; March L; Bertouch JV; Day RO
    Med J Aust; 2004 Oct; 181(8):457; discussion 457-8. PubMed ID: 15487967
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 13. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
    Smolen JS; Aletaha D
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
    [No Abstract]   [Full Text] [Related]  

  • 14. Escalated conventional therapy for rheumatoid arthritis patients.
    Smith MD
    Rheumatology (Oxford); 2004 Sep; 43(9):1199; author reply 1199-1200. PubMed ID: 15317963
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 16. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease.
    Kavanaugh AF; Mayer LF; Cush JJ; Hanauer SB
    Am J Med; 2011 Apr; 124(4 Suppl):e1-18. PubMed ID: 21531240
    [No Abstract]   [Full Text] [Related]  

  • 17. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.